Viruses do not conquer cells alone — they recruit the cell's own guardians to serve their ends. In studying chikungunya-infected macrophages, researchers have traced that complicity to a single protein, HSC71, a molecular chaperone whose ordinary duty is to keep cellular life in order. By mapping thousands of altered proteins through mass spectrometry, the team identified this housekeeping molecule as a critical enabler of viral replication — and found that silencing it slows the virus without harming the cell itself. The discovery opens a quieter kind of antiviral strategy: not attacking the
Heat shock protein HSC71 identified as key host factor enabling chikungunya virus replication
The virus could not replicate without this single host protein.
Mark
So they found that this one protein, HSC71, is essential for the virus to replicate. How confident are we that it's actually the virus using it, and not just a side effect of the cell's stress response?
Mimi
That's the right question. What they showed is correlation and functional dependence—when you block HSC71, viral replication drops. But they're honest about it: the direct mechanism isn't yet clear. It could be that the virus actively hijacks HSC71, or that the virus creates conditions where the cell needs more HSC71 to survive, and the virus benefits from that.
Luke
And the sample size here—they worked with RAW264.7 macrophages, which is a mouse cell line. We don't know yet if human macrophages behave the same way, or if the finding holds in actual infected tissue versus a petri dish.
Mimi
True. But that's why they call it a starting point. The proteomics work is solid—2,096 proteins measured, statistical thresholds met. The inhibition experiment is clean. It's a foundation.
Mark
If HSC71 is a housekeeping protein, won't blocking it affect other viruses too? Could this be a broad antiviral?
Mimi
Possibly. Heat shock proteins are ancient, conserved across many pathogens. But that's also the risk—you might block HSC71 and affect the cell's ability to handle other stresses.
Luke
And we should note: they tested this in cells, not in animals or humans. The jump from "reduced replication in a dish" to "viable drug" is substantial. But yes, the fact that blocking it didn't kill the cells is encouraging.
Mark
What comes next for them?
Mimi
They need to understand the mechanism. Does the virus bind directly to HSC71? Does it need HSC71 to process its own proteins? Once you know that, you can design inhibitors that are more specific, less likely to have side effects.
Luke
And they need to test it in more complex systems—tissues, animal models—to see if the effect holds and whether there's toxicity at doses that matter therapeutically.
Il Polso
- Chikungunya virus, which causes debilitating joint pain and has no approved antiviral treatment, continues to spread through mosquito populations with few therapeutic options to counter it.
- A proteomics sweep of infected immune cells revealed a landscape of 2,096 altered proteins — a signal of deep cellular disruption as the virus commandeers the machinery of its host.
- Within that complexity, HSC71 emerged as a hub protein, upregulated and connected to multiple metabolic and regulatory pathways that the virus appears to depend on for replication.
- Pharmacological inhibition of HSC71 significantly reduced viral replication in cell cultures — and crucially, the immune cells survived the intervention without measurable toxicity.
- The precise mechanism linking HSC71 to chikungunya's life cycle remains unresolved, but the target is now identified and the therapeutic rationale is clear enough to drive the next phase of research.
Viruses do not conquer cells alone — they recruit the cell's own guardians to serve their ends. In studying chikungunya-infected macrophages, researchers have traced that complicity to a single protein, HSC71, a molecular chaperone whose ordinary duty is to keep cellular life in order. By mapping thousands of altered proteins through mass spectrometry, the team identified this housekeeping molecule as a critical enabler of viral replication — and found that silencing it slows the virus without harming the cell itself. The discovery opens a quieter kind of antiviral strategy: not attacking the pathogen directly, but withdrawing the hospitality it depends upon.
Chikungunya virus does not replicate in isolation — it borrows the cell's own infrastructure to do its work. A research team set out to map exactly which cellular systems the virus depends on, beginning with infected macrophages, the immune cells that are among the first to encounter the pathogen in the body.
Using mass spectrometry, they compared the protein landscape of infected and uninfected cells, finding 2,096 proteins with altered levels. Narrowing their focus to the most significantly changed — 140 upregulated, 72 downregulated — they followed a recurring signal: stress response pathways were being activated throughout the infected cell. Among the most consistently elevated proteins was HSC71, a molecular chaperone whose normal role is to help other proteins fold correctly and maintain their shape. Network analysis revealed it was not acting alone; it sat at the center of multiple metabolic and regulatory pathways the virus appeared to need.
The team then asked what would happen if HSC71 were blocked. Using pharmacological inhibitors, they suppressed the protein's activity in infected cells and found that viral replication dropped significantly — without killing the macrophages themselves. That absence of toxicity is a meaningful distinction in drug development, where many antiviral candidates fail because they damage the patient's own cells alongside the pathogen.
How exactly HSC71 enables chikungunya replication remains an open question — whether the virus uses it to fold its own proteins, or to manipulate the cell's metabolic state, is still unknown. But the dependency is now documented, and the door to a new class of host-directed antiviral therapy is visible. Future research into this mechanism could yield treatments that interrupt the virus's life cycle by withdrawing the cellular hospitality it relies upon.
Chikungunya virus arrives in a cell and begins its work of replication, but it does not do this alone. It hijacks the machinery already present—the proteins that keep a cell functioning, the pathways that maintain order. A team of researchers set out to map exactly which of those cellular systems the virus depends on, and what they found points toward a single protein that might be the virus's Achilles heel.
The work began with infected macrophages, the immune cells that are among the first to encounter chikungunya in the body. Using mass spectrometry, a technique that identifies and measures proteins with extraordinary precision, the researchers compared the protein landscape of infected cells to uninfected ones. The difference was stark: 2,096 proteins showed altered levels. But within that noise, a pattern emerged. Two hundred twelve proteins were significantly changed—140 ramped up, 72 dialed down. The researchers were looking for the ones that mattered most.
When they mapped these altered proteins onto known cellular pathways, stress response kept appearing. The cell, under siege from the virus, was activating its emergency systems. Among the proteins most consistently upregulated was heat shock cognate 71, or HSC71, a protein normally tasked with helping other proteins fold correctly and maintain their shape. It is a housekeeping protein, one that cells rely on to stay functional. But in the presence of chikungunya, it was being called upon at higher levels. Network analysis showed HSC71 was not working in isolation—it was connected to multiple metabolic and regulatory pathways that the virus seemed to need.
The researchers then asked a direct question: what happens if we turn HSC71 off? They used pharmacological inhibitors to block the protein's function in infected cells. The result was unambiguous. Viral replication dropped significantly. The virus could not replicate as efficiently without access to this single host protein. Equally important, the cells themselves did not die from the treatment. There was no widespread toxicity, no collateral damage to the macrophage.
This distinction matters enormously for drug development. Many antiviral approaches fail not because they stop the virus, but because they poison the patient's own cells in the process. Here was a target that appeared to slow the virus without that trade-off. The researchers acknowledge that the precise mechanism—exactly how HSC71 enables chikungunya replication—remains to be worked out. Does the virus use it to fold its own proteins? Does it need HSC71 to manipulate the cell's metabolic state? Those questions remain open. But the door is now visible. Future work to understand HSC71's role in chikungunya infection could lead toward new treatments that exploit this dependency, potentially offering a way to interrupt the virus's life cycle without harming the immune cells trying to fight it.
Citazioni salienti
Host protein homeostasis and phosphorylation-dependent pathways may be implicated in chikungunya infection within macrophages— Research findings
Vuoi la storia completa?
Leggi l'originale su Nature ↗